Ironwood Pharmaceuticals (IRWD) risk factors, FY2024 10-K

Risks Related to LINZESS, Apraglutide and Other Product Candidates

1. 01We are highly dependent on the commercial success of LINZESS (linaclotide) in the U.S. for the foreseeable future
2. 02We are subject to uncertainty relating to pricing and reimbursement policies in the U.S., including recent and future healthcare reform measures, which, if not favorable for our products, could hinder or prevent our products’ commercial success
3. 03Healthcare reform and other governmental and private payor initiatives may have an adverse effect upon, and could prevent, our products’ or product candidates’ commercial success
4. 04Adoption of new healthcare reform legislation at the federal or state level could negatively affect demand for, or pricing of, our products or product candidates if approved for sale
5. 05We must work effectively and collaboratively with AbbVie to market and sell LINZESS in the U.S., and we must adapt our commercial model and market strategy to the evolving landscape for LINZESS to achieve its maximum commercial potential
6. 06Upon the closing of the VectivBio Acquisition, we added apraglutide, a next generation, long-acting GLP-2 analog in development for SBS patients who are dependent on PS, to our pipeline
7. 07As part of our growth strategy, we intend to explore further linaclotide development opportunities as well as to advance the development of our other pipeline programs, such as apraglutide, through internal or external opportunities
8. 08U.S. FDA or in other countries or harm linaclotide’s reputation in the marketplace, each of which could materially harm our revenues from linaclotide
9. 09Delays in the completion of clinical testing of any of our products or product candidates could result in increased costs and delay or limit our ability to generate revenues
10. 10The pricing of apraglutide and our other product candidates, if and when approved for marketing, will depend in part on pricing and reimbursement strategies adopted by our competitors
11. 11We face competition and new products may emerge that provide different or better alternatives for treatment of the conditions that our products are approved to treat
12. 12Our products or product candidates may cause undesirable side effects or have other properties that could delay or prevent their development, create unpredictable clinical trial results, impact its regulatory approval or limit their commercial potential
13. 13Even though linaclotide is approved for marketing in the U.S. and in a number of other countries, we or our partners may never receive approval to commercialize linaclotide in additional parts of the world

Risks Related to Our Growth Strategy

1. 14If we are unable to execute on our strategy to in-license or acquire externally developed products or product candidates, or engage in other transactions with value creation potential, our business and prospects would be materially adversely affected
2. 15If we are unable to successfully partner with other companies to develop and commercialize products and/or product candidates, our ability to grow would be impaired and our business would be adversely affected

Risks Related to the VectivBio Acquisition

1. 16In December 2023, we completed the VectivBio Acquisition. We may not realize the expected benefits from such acquisition because of integration difficulties or other challenges

Risks Related to Our Dependence on Third Parties

1. 17Manufacturers of our products may be unable to comply with these GMP requirements and with other regulatory requirements. We have little control over compliance with these regulations and standards by our partners and the third-party manufacturers we or our partners engage

Risks Related to Regulatory, Legal and Compliance Matters

1. 18We face potential product liability exposure, and, if claims brought against us are successful, we could incur substantial liabilities
2. 19We will incur significant liability if it is determined that we are promoting any “off-label” uses of our products
3. 20If we fail to comply with healthcare and other regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected
4. 21individual states have begun establishing Prescription Drug Affordability Boards (or similar entities) to review high-cost drugs and, in some cases, set upper payment limits. Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation
5. 22The VectivBio Acquisition increases our exposure to doing business in foreign jurisdictions

Risks Related to Intellectual Property

1. 23Limitations on our ability to obtain patent protection and/or the patent rights relating to our products and our product candidates may limit our ability to prevent third parties from competing against us
2. 24Our success depends on our ability to obtain and maintain sufficient patent protection for our products and product candidates, preserve our trade secrets, prevent third parties from infringing upon our proprietary rights and operate without infringing upon the proprietary rights of others
3. 25future. For example, such changes may increase the costs and complexity associated with obtaining, enforcing or defending our patents, including in ANDA litigation
4. 26Our commercial success depends on our ability, and the ability of our partners, to develop, manufacture, market and sell our products and use our proprietary technologies without infringing the proprietary rights of third parties
5. 27We may be unable to maintain the benefits associated with orphan drug designation, including market exclusivity, which may harm our business
6. 28our partners, misappropriation of our proprietary rights, particularly in countries where the laws may not protect those rights as fully as in the U.S

Risks Related to Our Finances and Capital Requirements

1. 29We incurred significant losses from our inception in 1998 through the year ended December 31, 2018, and we may incur losses in future periods
2. 30We may need additional funding and may be unable to raise capital when needed, which could cause us to delay, reduce or eliminate our corporate or product development or commercialization efforts
3. 31Our ability to pay principal of and interest on our outstanding debt will depend in part on the receipt of payments from AbbVie under our collaboration agreement for North America
4. 32As of December 31, 2024, we had total indebtedness of $585.0 million and available cash and cash equivalents of $88.6 million
5. 33borrowed $400.0 million to fund a portion of the consideration paid to purchase VectivBio’s outstanding ordinary shares in connection with the VectivBio Acquisition
6. 34To the extent we become subject to such covenants, our ability to comply with such covenants in future periods will depend on our ongoing financial and operating performance, which in turn will be subject to economic conditions and to financial, market and competitive factors, many of which are beyond our control
7. 35The capped call transactions entered into in connection with our Convertible Senior Notes may affect the value of our Class A Common Stock
8. 36Our quarterly and annual operating results may fluctuate significantly
9. 37Our ability to use foreign tax loss carryforwards acquired in the VectivBio Acquisition may be limited
10. 38If the distribution of the shares of Cyclerion Therapeutics, Inc., or Cyclerion, common stock in connection with the Separation is not generally tax- free for U.S. federal income tax purposes, we and our stockholders could be subject to significant tax liabilities
11. 39We may not be able to manage our business effectively if we lose any of our current management team or if we are unable to attract, motivate and retain key personnel
12. 40Security breaches and other disruptions to our information technology structure could compromise our information, disrupt our business and expose us to liability, which would cause our business and reputation to suffer
13. 41Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could negatively impact the market price of our Class A Common Stock
14. 42We expect that the price of our Class A Common Stock will fluctuate substantially
15. 43Our business could be negatively affected as a result of a proxy contest or certain other stockholder actions